Can measuring drug levels reduce chemo side effects in leukemia patients?
NCT ID NCT07254312
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how much venetoclax is in the blood of people with acute myeloid leukemia (AML) who are in remission and still receiving treatment. The goal is to see if higher drug levels are linked to more severe side effects, like low white blood cell counts. By understanding this, doctors hope to adjust doses to make treatment safer and more tolerable. The study will enroll 14 participants and measure venetoclax levels using a special lab test.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax
What this could lead to
If successful, this could help doctors personalize venetoclax dosing to reduce severe side effects while keeping leukemia in remission.
What could go wrong
This is a very small, early observational study with only 14 participants. It is not testing a new treatment, so it may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Policlinico San Matteo, SC Oncologia
RECRUITINGPavia, Pavia, 27100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••